Thoughts on this company. I like the market but am concerned about the execution.
V1
International Isotopes Inc Obtains State Approval for Increased Production Of Medical Radioisotopes
- License Permits Production of Commercial Quantities Of Radioisotopes on LINAC -
DENTON, Texas, Nov. 30 /PRNewswire/ -- International Isotopes Inc (Nasdaq: INIS, BSE: ITL) (I3), a contract manufacturer of finished radiopharmaceuticals and a commercial producer of radioisotopes, pharmaceutical grade radiochemicals and medical devices, today announced the Texas Department of Health, Bureau of Radiation Control (BRC) approved amendments to the I3's operational and development licenses, which will permit the Company to utilize its LINAC to produce commercial quantities of radioisotopes for use in diagnostic and therapeutic nuclear medicine.
``The approval of this license is a major step forward for the Company as we move toward commercial production of our products. Previously this year, the State granted a license to produce limited quantities of radioisotopes. Our customers have waited expectantly for this expanded authorization, which now permits I3 to receive, manufacture, sell and distribute commercial quantities of radioisotopes, radiochemicals and radiopharmaceuticals,' stated Dr. Ira Lon Morgan, Chairman and Treasurer.
Dr. Morgan added, ``The wide range of products International Isotopes plans to introduce to the market over the next few years will include: Tl-201 for the diagnosis of heart disease; I-123 for the diagnosis of thyroid cancer, thyroid disorders and the detection of Parkinson's disease; In-111 for the diagnosis of lower organ diseases and treatment of colon and liver cancer; Ga- 67 for diagnosis of urinary infections; I-125 and Pd-103 used in the production of brachytherapy seeds for prostrate cancer; Sr-89 for pain palliation of bone cancer; I-131 for treatment of thyroid cancer; Ho-166 for treatment of multiple myeloma; F-18 for diagnosis of brain tumors and function; Y-90 for use in cancer therapy and Co-57 for calibration of diagnostic imaging systems. These products will be added to the list of radioisotopes currently produced by International Isotopes Idaho Inc.'
International Isotopes Inc, headquartered in Denton, Texas, is initiating production operations to be the premier supplier of finished radiopharmaceuticals, pharmaceutical grade radiochemicals, radioisotopes and brachytherapy devices used in nuclear medicine for the diagnostic and therapeutic treatment of cancer and other diseases.
I3 Safe Harbor Statement
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the ability to meet time schedules, the need to raise additional capital, the development of competitive products by others and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update statements in this press release. |
